Suppression of Major Histocompatibility Complex (MHC) Class I and II Mediates Resistance to Anti-PD-1 in Lung Adenocarcinoma Tumors That Can Be Overcome by Radiation Therapy

被引：3
|
作者：
Wang, X. [1 ]
Schoenhals, J. E. [1 ]
Valdecanas, D. R. [1 ]
Li, A. [1 ]
Ye, H. [1 ]
Zhang, F. [2 ]
Tang, M. [3 ]
Tang, C. [4 ]
Liu, C. G. [5 ]
Liu, X. [5 ]
Komaki, R. U. [4 ]
Gomez, D. R. [4 ]
Chang, J. Y. [4 ]
Cortez, M. A. [1 ]
Welsh, J. W. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2016.06.224
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
201
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 20 条
  • [1] Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
    Wang, Xiaohong
    Schoenhals, Jonathan E.
    Li, Ailin
    Valdecanas, David R.
    Ye, Huiping
    Zang, Fenglin
    Tang, Chad
    Tang, Ming
    Liu, Chang-Gong
    Liu, Xiuping
    Krishnan, Sunil
    Allison, James P.
    Sharma, Padmanee
    Hwu, Patrick
    Komaki, Ritsuko
    Overwijk, Willem W.
    Gomez, Daniel R.
    Chang, Joe Y.
    Hahn, Stephen M.
    Cortez, Maria Angelica
    Welsh, James W.
    CANCER RESEARCH, 2017, 77 (04) : 839 - 850
  • [2] Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma
    Johnson, Amber M.
    Bullock, Bonnie L.
    Neuwelt, Alexander J.
    Poczobutt, Joanna M.
    Kaspar, Rachael E.
    Li, Howard Y.
    Kwak, Jeff W.
    Hopp, Katharina
    Weiser-Evans, Mary C. M.
    Heasley, Lynn E.
    Schenk, Erin L.
    Clambey, Eric T.
    Nemenoff, Raphael A.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (08): : 2295 - 2307
  • [3] Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy
    Inozume, Takashi
    Yaguchi, Tomonori
    Ariyasu, Ryo
    Togashi, Yosuke
    Ohnuma, Takehiro
    Honobe, Akiko
    Nishikawa, Hiroyoshi
    Kawakami, Yutaka
    Kawamura, Tatsuyoshi
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (07) : 1490 - 1496
  • [4] Major histocompatibility complex (MHC) class I and II and intercellular adhesion molecule (ICAM)-1 expression in oesophageal carcinoma
    Rockett, J
    Darnton, S
    Crocker, J
    Matthews, H
    Morris, A
    RECENT ADVANCES IN DISEASES OF THE ESOPHAGUS: SELECTED PAPERS IN 6TH WORLD CONGRESS OF THE INTERNATIONAL SOCIETY FOR DISEASES OF THE ESOPHAGUS, 1996, : 45 - 49
  • [5] Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)
    Roemer, Margaretha G. M.
    Redd, Robert A.
    Cader, Fathima Zumla
    Pak, Christine J.
    Abdelrahman, Sara
    Ouyang, Jing
    Sasse, Stephanie
    Younes, Anas
    Fanale, Michelle A.
    Santoro, Armando
    Zinzani, Pier Luigi
    Timmerman, John M.
    Collins, Graham
    Ramchandren, Rod
    Cohen, Jonathon B.
    De Boer, Jan Paul
    Kuruvilla, John
    Savage, Kerry J.
    Trneny, Marek
    Ansell, Stephen M.
    Sacchi, Mariana
    Farsaci, Benedetto
    Sumbul, Anne
    Armand, Philippe
    Neuberg, Donna S.
    Pinkus, Geraldine S.
    Ligon, Azra H.
    Rodig, Scott J.
    Shipp, Margaret A.
    BLOOD, 2017, 130
  • [6] MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Breast Cancer Patients
    Maniaci, Joseph
    Mills, Anne
    Dillon, Patrick
    Gaughan, Elizabeth
    Jenkins, Taylor
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 160 - 161
  • [7] MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Breast Cancer Patients
    Maniaci, Joseph
    Mills, Anne
    Dillon, Patrick
    Gaughan, Elizabeth
    Jenkins, Taylor
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 160 - 161
  • [8] Programmed Cell Death Ligand 1 (PD-L1) and Major Histocompatibility Complex Class I (MHC Class I) Expression Patterns and Their Pathologic Associations in Triple-Negative Breast Cancer
    Kaewkedsri, Ponkrit
    Intarawichian, Piyapharom
    Jessadapattarakul, Sirawich
    Kunprom, Waritta
    Koonmee, Supinda
    Thanee, Malinee
    Somintara, Ongart
    Wongbuddha, Anongporn
    Chadbunchachai, Payia
    Nawapun, Supajit
    Aphivatanasiri, Chaiwat
    BREAST CANCER-TARGETS AND THERAPY, 2025, 17 : 123 - 143
  • [9] Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance
    James, Jamaal L.
    Taylor, Brandie C.
    Axelrod, Margaret L.
    Sun, Xiaopeng
    Guerin, Lindsey N.
    Gonzalez-Ericsson, Paula, I
    Wang, Yu
    Sanchez, Violeta
    Fahey, Catherine C.
    Sanders, Melinda E.
    Xu, Yaomin
    Hodges, Emily
    Johnson, Douglas B.
    Balko, Justin M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [10] Analysis of the tumor reactivity of tumor-infiltrating lymphocytes in a metastatic melanoma lesion that lost MHC class I expression after anti-PD-1 therapy
    Inozume, T.
    Yaguchi, T.
    Ariyasu, R.
    Togashi, Y.
    Nishikawa, H.
    Kawakami, Y.
    Kawamura, T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S134 - S134
12